Tony Chen represents technology and life science companies in their intellectual property matters in China and in the United States. In China, Tony has assisted multinational companies in enforcing their intellectual property rights in civil and criminal actions and in reducing intellectual property risks in R&D collaborations. He has represented Chinese companies in defending infringement lawsuits and licensing technology on a worldwide basis.

Tony's recent representative matters include: defending a Fortune 500 company in a patent infringement lawsuit in China, defending a Chinese patent of a global top 10 biotechnology company in an invalidation action, fighting pharmaceutical counterfeiting in China for a global top 10 biotechnology company, representing multinational companies in contract research and R&D collaborations in China, defending Chinese companies in patent infringement lawsuits in the U.S. in federal district courts and at the International Trade Commission, and representing Chinese biotechnology companies in technology licensing. Representative multinational clients include Abbott, Cabot, Celgene, Chevron, General Motors, GSK, Kleiner Perkins Caufield & Byers, Lowe's, Pfizer, and Vivo Ventures. Representative Chinese clients include Baosteel, ChemPartner, Founder, Legend Holdings, Shanghai Huaming Power Equipment, Sinorgchem, Ventec Electronics, and Zensun.

Tony writes and speaks frequently about the development of intellectual property law and the life sciences industry in China. His commentaries have reached the international legal and business community through the Economist, Financial Times, Business Week, and American Lawyer. Tony also has consulted technology parks in Shanghai and Suzhou on life sciences industry and intellectual property matters.

http://www.jonesday.com/tonychen/#